Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Incyte Corp Market Cap
Based on ratings from 26 stock analysts, the Incyte Corp stock price is expected to increase by 8.04% in 12 months. This is calculated by using the average 12-month stock price forecast for Incyte Corp. The lowest target is $52 and the highest is $97. Please note analyst price targets are not guaranteed and could be missed completely.
Incyte Corp has a total of 26 Wall St Analyst ratings. There are 12 buy ratings, 13 ratings, and 1 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Incyte Corp will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of INCY.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Brian Abrahams RBC Capital | Sector Perform | $74 | Maintains | Nov 19, 2024 |
| Eric Schmidt Cantor Fitzgerald | Neutral | Reiterates | Nov 19, 2024 | |
| Brian Abrahams RBC Capital | Sector Perform | $80 | Maintains | Nov 14, 2024 |
| Vikram Purohit Morgan Stanley | Equal-Weight | $69 | Maintains | Oct 30, 2024 |
| Tazeen Ahmad B of A Securities | Buy | $90 | Upgrade | Oct 30, 2024 |
| Jay Olson Oppenheimer | Outperform | $82 | Maintains | Oct 30, 2024 |
| Evan Seigerman BMO Capital | Underperform | $52 | Reiterates | Oct 30, 2024 |
| David Lebowitz Citigroup | Buy | $97 | Maintains | Oct 30, 2024 |
| Derek Archila Wells Fargo | Equal-Weight | $68 | Maintains | Oct 30, 2024 |
| Salveen Richter Goldman Sachs | Neutral | $70 | Maintains | Oct 30, 2024 |
| Jessica Fye JP Morgan | Neutral | $71 | Maintains | Oct 30, 2024 |
| Brian Abrahams RBC Capital | Sector Perform | $72 | Maintains | Oct 30, 2024 |
| Jessica Fye JP Morgan | Neutral | $65 | Maintains | Oct 23, 2024 |
| Derek Archila Wells Fargo | Equal-Weight | $62 | Maintains | Oct 10, 2024 |
| Andy Chen Wolfe Research | Outperform | Initiates | Oct 1, 2024 | |
| Srikripa Devarakonda Truist Securities | Hold | $74 | Downgrade | Sep 18, 2024 |
| Reni Benjamin JMP Securities | Market Perform | Reiterates | Sep 17, 2024 | |
| Michael Schmidt Guggenheim | Buy | $92 | Maintains | Sep 16, 2024 |
| Eric Schmidt Cantor Fitzgerald | Neutral | Reiterates | Sep 16, 2024 | |
| Tazeen Ahmad B of A Securities | Neutral | $68 | Maintains | Sep 16, 2024 |
When did it IPO
1993
Staff Count
2,524
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Herve Hoppenot
Market Cap
$14.63B
In 2023, INCY generated $3.70B in revenue, which was a increase of 8.87% from the previous year. This can be seen as a signal that INCY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 09 Dec 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky is investigating Incyte Corporation (NASDAQ: INCY) for potential federal securities law violations after it paused enrollment in a Phase 2 study for drug INCB000262 due to toxicology concerns.
Why It Matters - The investigation into Incyte Corporation for potential securities law violations, coupled with the pause in drug trials, raises concerns about regulatory compliance and future revenue, impacting stock performance.
Mon, 09 Dec 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - INCY's phase III study of retifanlimab with platinum-based chemotherapy for metastatic non-small cell lung cancer has successfully met its primary and secondary endpoints.
Why It Matters - Successful phase III results for INCY's retifanlimab could lead to FDA approval, boosting revenue potential and market confidence in the company's oncology pipeline.
Mon, 09 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Exelixis (EXEL) and Incyte (INCY) are two notable stocks in the Medical - Biomedical and Genetics sector, attracting interest from value investors.
Why It Matters - The comparison between Exelixis and Incyte highlights potential investment opportunities in the biomedical sector, influencing stock selection for value-focused strategies.
Thu, 05 Dec 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky is investigating Incyte Corporation (NASDAQ: INCY) for possible federal securities law violations after it paused enrollment in a Phase 2 study due to preclinical toxicology findings.
Why It Matters - The investigation into Incyte Corporation and the paused drug trial may indicate potential legal and financial risks, impacting investor confidence and stock performance.
Fri, 06 Dec 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky is investigating Incyte Corporation (NASDAQ: INCY) for potential federal securities law violations following its pause in enrollment for a Phase 2 study due to toxicology concerns.
Why It Matters - The investigation into Incyte Corporation for potential securities law violations and the pause in drug enrollment may signal regulatory issues, impacting stock performance and investor confidence.
Fri, 06 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Incyte has reported inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4).
Why It Matters - Incyte's inducement grants may signal new hiring and strategic growth, potentially impacting stock performance and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
